文献速递脑血管病

疾病管理项目预防缺血性卒中复发的随机对照试验

Effects of a Disease Management Program for Preventing Recurrent Ischemic Stroke.
PubMed 文献 · Stroke · 2019-01-01

本研究为前瞻性随机开放标签平行组试验,纳入321例40-80岁、近1年内发生缺血性卒中或短暂性脑缺血发作的门诊患者,随机分为疾病管理项目干预组(n=156)和常规护理组(n=165)。主要终点为Framingham风险评分(一般心血管病10年风险)较基线的变化,结果显示两组在各随访时间点均无显著差异;卒中复发在干预组有降低趋势但未达统计学显著(HR 0.49,95%CI 0.19-1.29)。结论未能证实疾病管理项目干预的明确获益。

要点

  • 疾病管理项目未显著改善Framingham风险评分。
  • 卒中复发在干预组有降低趋势但无统计学意义。
  • 该干预策略未能显示明确临床获益。

核心结论

  • 未能证实疾病管理项目干预对缺血性卒中患者具有明确获益。

研究设计与样本

  • 前瞻性随机开放标签平行组研究,纳入321例40-80岁近1年内发生缺血性卒中或短暂性脑缺血发作的门诊患者。
  • 按缺血性卒中亚型分层后随机分为疾病管理项目干预组(n=156)和常规护理组(n=165)。

主要发现

  • 主要终点Framingham风险评分较基线的变化在各随访时间点两组均无显著差异。
  • 卒中复发在干预组有降低趋势但无显著差异(HR 0.49,95%CI 0.19-1.29)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Disease management is a healthcare strategy that includes self-management education and treatment coordination. We conducted a randomized controlled trial to determine whether a disease management program intervention could improve risk factor profiles and, thus, reduce the recurrence of stroke and other cardiovascular diseases. Methods- This study is a prospective randomized, open-label, parallel group study involving outpatients with a history of stroke. Between September 2010 and November 2012, we enrolled patients aged between 40 and 80 years who experienced their last ischemic stroke event or transient ischemic attack within 1 year. After stratifying by the ischemic stroke subtype, 321 subjects (67.5±8.5 years, 95 female) were randomly assigned to either the disease management program intervention group (n=156) or the usual care group (n=165). The primary end point of this study was the difference in the Framingham risk score (general cardiovascular disease 10-year risk) from baseline. The secondary end points of this study included stroke recurrence, onset of cardiovascular disease, all-cause mortality, and all vascular events. Results- Regarding the primary end point, there was no significant difference in the changes in the Framingham risk score at any follow-up time between the groups. The incidence of stroke recurrence tended to be lower in the disease management program intervention group, although no significant difference was found (hazard ratio, 0.49; 95% CI, 0.19-1.29). Conclusions- We were unable to demonstrate a clear benefit of disease management program intervention. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT02121327.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Fukuoka Y, Hosomi N, Hyakuta T, et al. Effects of a Disease Management Program for Preventing Recurrent Ischemic Stroke. Stroke. 2019. PMID: 30802185. doi:10.1161/STROKEAHA.118.020888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。